SLC6A3 and Parkinson disease: Since differing entities of our cohort might lead to heterogeneous results, further longitudinal investigations, such as using dopamine transporter or cardiac imaging to discriminate between risks of conversion to PD vs. MSA, may also help to clarify this question.